SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: FORM 10-Q þ For the quarterly period ended

[FORM 10-Q þ For the quarterly period ended June 30, 2009 or o For the transition period from Skystar Bio-Pharmaceutical Company (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer EX-32.1 5 v156959_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v156959_ex32-2.htm]

By | 2016-03-01T07:24:19+00:00 August 14th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]

By | 2016-03-01T07:25:11+00:00 August 14th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI’AN,

[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]

By | 2016-03-01T07:26:43+00:00 August 14th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q For the quarterly period ended June 30, 2009 or o For the transition period fromystar Bio-Pharmaceuticalmpany (Exact name of small business issuerecified in its charter) Nevada (State or other jurisdiction oforporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South,] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer v156959_ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) v156959_ex32-2.htm 6 EX-32.2]

By | 2016-02-05T05:14:11+00:00 August 14th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: FORM 10-Q For the quarterly period ended June

[FORM 10-Q For the quarterly period ended June 30, 2009 or o For the transition period fromystar Bio-Pharmaceuticalmpany (Exact name of small business issuerecified in its charter) Nevada (State or other jurisdiction oforporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South,] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer v156959_ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) v156959_ex32-2.htm 6 EX-32.2]

By | 2016-02-05T05:15:03+00:00 August 14th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA August 14, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS Revenuesreased 39.4% year-over-year to $6.2 million Gross margin improved to 52.6% from 51.6% in the second quarter of 2008ome from operationsreased by 37.6% year-over-year to $1.7 million]

By | 2016-02-05T05:16:05+00:00 August 14th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI’AN,

[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA August 14, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS Revenuesreased 39.4% year-over-year to $6.2 million Gross margin improved to 52.6% from 51.6% in the second quarter of 2008ome from operationsreased by 37.6% year-over-year to $1.7 million]

By | 2016-02-05T05:17:17+00:00 August 14th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One)  June 30, 2009 For the quarterly period ended  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The] [EX-10.1 2 ex10-1.htm] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T15:54:06+00:00 August 13th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One)  June 30, 2009

[FORM 10-Q (Mark One)  June 30, 2009 For the quarterly period ended  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The] [EX-10.1 2 ex10-1.htm] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T15:55:49+00:00 August 13th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar